Cocaine Abuse and Attention Deficit Disorder - 3
Launched by NATIONAL INSTITUTE ON DRUG ABUSE (NIDA) · Sep 20, 1999
Trial Information
Current as of January 13, 2025
Completed
Keywords
ClinConnect Summary
To evaluate the safety and efficacy of methylphenidate and bupropion in treating individuals with adult Attention Deficit Disorder.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • current adult ADHD current cocaine dependence
- Exclusion Criteria:
- • no current major depression
Trial Officials
Herbert Kleber, M.D.
Principal Investigator
New York State Psychiatric Institute
About National Institute On Drug Abuse (Nida)
The National Institute on Drug Abuse (NIDA) is a leading federal agency within the U.S. Department of Health and Human Services, dedicated to advancing the understanding of drug abuse and addiction through rigorous scientific research. NIDA's mission encompasses the exploration of the biological, behavioral, and social aspects of substance use disorders, facilitating the development of effective prevention and treatment strategies. By funding and conducting innovative clinical trials, NIDA aims to translate research findings into practical solutions that improve public health and inform policy, ultimately contributing to the reduction of substance-related harm in communities across the nation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials